Incidence and Echocardiographic Predictors of HFpEF in High-Risk Population Afferent to Italian Echo-labs Network

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

1000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-03-02

Study Completion Date

2025-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The evolving definitions of HF, the increasing attention of the medical community, and the aging of the population are some of the factors contributing to a still debated incidence and prevalence of HFpEF across the general and specific populations. Despite the current decline in new HF cases, HFpEF shows stable incidence according to epidemiological studies. Cardiovascular risk factors, such as a long history of hypertension, diabetes, obesity, and others seem to be associated with a higher HFpEFincidence. Nevertheless, the potential echocardiographic predictors of HFpEF have not been defined yet.

Hypothesis In a population at high risk for HFpEF, collected using a multicenter echo-lab network, the real incidence of HFpEF cases and echocardiographic predictors can be identified.

Aim 1: to define the incidence of HFpEF in a high-risk cohort of patients afferent to the Italian echo-lab network.

Aim 2: to explore the standard (2D and Doppler data) and advanced (LV and LA strain) echocardiographic parameters associated with and potential predictors of HFpEF.

Methods This is a multicenter, prospective, observational study involving an Italian echo labs network. According to inclusion and exclusion criteria, patients will be enrolled during standard echocardiographic evaluation. After signing informed consent, clinical and echocardiographic data will be collected. Thereafter, they will be followed up for major clinical events (cardiovascular death, HF requiring hospitalization, myocardial infarct, and atrial fibrillation) for a period of 12 months

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Prediction of the Development of Heart Failure With Preserved Ejection Fraction

NCT04894968

Heart Failure With Preserved Ejection Fraction

UNKNOWN

Right Ventricular Dysfunction in Chronic Heart Failure

NCT06002321

Chronic Heart Failure Right Ventricular Dysfunction Right Heart Failure

NOT_YET_RECRUITING

The Heart Failure With Preserved Ejection Fraction (HFpEF) Pathophysiology Study.

NCT03186833

Heart Failure With Normal Ejection Fraction

COMPLETED

Handled Echocardiography and Chronic Heart Failure

NCT01365325

Chronic Heart Failure

COMPLETED NA

Retrospective Observational Analysis of a Cohort With Heart Failure With Preserved Ejection Fraction

NCT04233086

Heart Failure With Preserved Ejection Fraction

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Heart Failure Heart Failure With Preserved Ejection Fraction

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Heart Failure with preserved Ejection Fraction (HFpEF)

After signing informed consent, clinical and echocardiographic data will be collected. Thereafter, they will be followed up for major clinical events (cardiovascular death, HF requiring hospitalization, myocardial infarction, and atrial fibrillation) for a period of 12 months.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age \>65 years
* Echocardiographic LV EF \>50%
* Diastolic dysfunction at echocardiography of at least grade 1
* LV hypertrophy defined as: linear LV mass \>115 in men, \>95 g/m2 in women
* Left atrium (LA) enlargement defined as LA volume \> 34 mL/ m2

Exclusion Criteria

* Severe chronic renal failure (GFR \<15)
* Severe chronic obstructive pulmonary disease (COPD) (FEV1 \<1)
* More than moderate valve disease
* Previous cardiac surgery
* Previous LV EF \<40%

Minimum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No